Press release
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
Two late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura®) in hidradenitis
About this update from Incyte Corporation
[{"type":"text","content":"\n\nTwo late-breaking abstracts have been accepted for oral presentation, including randomized studies evaluating ruxolitinib cream (Opzelura®) in hidradenitis suppurativa and povorcitinib (INCB54707) in prurigo nodularis\n\n\n\nAnalyst and investor event to discuss key data presentations scheduled for Monday, March 11, 2024 at 9:00 a.m. PT / 12:00 p.m. ET\n\n\n\n \n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.\n\n\n“We are pleased to convene at this year’s AAD Annual Meeting and share data, including two late-breaking presentations, from our growing dermatology portfolio,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Our presence at this year’s meeting showcases Incyte’s commitment to find solutions for patients where there continues to be critical unmet needs. We are excited to share clinical data evaluating ruxolitinib cream and povorcitinib in immune-mediated dermatologic conditions including atopic dermatitis, vitiligo, hidradenitis suppurativa and prurigo nodularis.”\n\n\nKey abstracts include:\n\n\nLate-Breaking Oral Presentations\n\n\nPrurigo Nodularis\n\n\nEfficacy and Safety of Povorcitinib in Patients with Prurigo Nodularis: Results From a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study (Session: S050 – Late-Breaking Research: Session 2. Sunday, March 10, 2024, 4:00 p.m. ET)\n\n\nHidradenitis Suppurativa\n\n\nEfficacy and Safety of Ruxolitinib Cream in Patients With Hidradenitis Suppurativa (Hurley Stage I and II): Results From a Randomized, Double-Blind, Vehicle-Controlled Phase 2 Study (Session: S050 – Late-Breaking Research: Session 2. Sunday, March 10, 2024, 4:10 p.m. ET)\n\n\ne-Posters with Mini Oral Presentation\n\n\nAtopic Dermatitis\n\n\nEfficacy of Ruxolitinib Cream for the Treatment of Atopic Dermatitis in Children Aged 2–","length":2960,"tagName":"div"}]